AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14983226 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 24
Study 14983226 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-dose aprotinin
Number of subjects: 24
Study 14983226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11795347 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (HRT)
Number of subjects: 0
Study 11795347 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9459084 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg i.m. leuprolide acetate (LA) every 4 weeks for 24 weeks
Number of subjects: 40
Study 9459084 — intervention group
Group type: COMPARATOR
Intervention: 3.7 mg LA combined with 1.25 mg oral conjugated equine estrogen (CEE) and 5 mg oral medroxyprogesterone acetate (MA)
Number of subjects: 40
Study 7934712 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive Explanation (EE)
Number of subjects: 136
Study 7934712 — intervention group
Group type: COMPARATOR
Intervention: Limited Explanation (LE)
Number of subjects: 136
Study 2455176 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms/day)
Number of subjects: 21
Study 2455176 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (30 mg/day)
Number of subjects: 21
Study 31156221 — intervention group
Group type: EXPERIMENTAL
Intervention: neuroleptic therapy in combination with intravenous infusions of remaxol (400.0 ml)
Number of subjects: 60
Study 31156221 — intervention group
Group type: COMPARATOR
Intervention: active placebo (0.9% sodium chloride solution, 400.0 ml)
Number of subjects: 60
Study 27956428 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI8897 (300, 1,000, or 3,000 mg intravenously or 100 or 300 mg intramuscularly)
Number of subjects: 136
Study 27956428 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI8897 (300 mg i.m.)
Number of subjects: 136
Study 27956428 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI8897 (i.m. dosing)
Number of subjects: 136
Study 27956428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 27956428 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI8897
Number of subjects: 136
Study 26115690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed high-intensity laser therapy (HILT) plus routine physical therapy program (RPTP)
Number of subjects: 61
Study 26115690 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser plus routine physical therapy program (RPTP)
Number of subjects: 61
Study 23557930 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1322322 (500-1500 mg)
Number of subjects: 52
Study 23557930 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1322322 (1000-1500 mg)
Number of subjects: 52
Study 23557930 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1322322
Number of subjects: 52
Study 23557930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 21747084 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 5) and pemetrexed (500 mg/m(2)) every 21 days for four cycles and thoracic radiation therapy (TRT) (70 Gy)
Number of subjects: 101
Study 21747084 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (AUC 5) and pemetrexed (500 mg/m(2)) every 21 days for four cycles and thoracic radiation therapy (TRT) (70 Gy) with cetuximab administered concurrent only with TRT
Number of subjects: 101
Study 19573486 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment (target serum level of lithium 0.5‐0.8 mmol/L)
Number of subjects: 71
Study 19573486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 16451765 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hygiene side (NH)
Number of subjects: 39
Study 16451765 — intervention group
Group type: COMPARATOR
Intervention: Hygiene side (H)
Number of subjects: 39
Study 15248052 — intervention group
Group type: EXPERIMENTAL
Intervention: New Carisolv gel (higher concentration of sodium hypochlorite)
Number of subjects: 170
Study 15248052 — intervention group
Group type: COMPARATOR
Intervention: Original Carisolv gel
Number of subjects: 170
Study 15248052 — intervention group
Group type: EXPERIMENTAL
Intervention: New Carisolv gel
Number of subjects: 170
Study 15248052 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemomechanical treatment (both gels)
Number of subjects: 170
Study 11391598 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (Arm B): 2-3 cycles of cisplatin (100 mg/m2 on Day 1) and 5-fluorouracil (1000 mg/m2 per day continuous infusion on Days 1-5)
Number of subjects: 48
Study 11391598 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Arm A): transthoracic esophagectomy plus two-field lymphadenectomy
Number of subjects: 48
Study 11391598 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (Arm B) with pathologic complete response
Number of subjects: 48
Study 11391598 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (Arm B) with partial response
Number of subjects: 48
Study 11391598 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (Arm B) responders vs nonresponders
Number of subjects: 48
Study 9258754 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (400 IU daily for at least 2 years)
Number of subjects: 81
Study 9258754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 8235809 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy with advice for daily life by a physiotherapist
Number of subjects: 473
Study 8235809 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound therapy by a physiotherapist
Number of subjects: 473
Study 8235809 — intervention group
Group type: COMPARATOR
Intervention: Usual care by the general practitioner
Number of subjects: 473
Study 3321756 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg Ibuprofen q.i.d. as pellets
Number of subjects: 10
Study 3321756 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg Ibuprofen b.i.d. as dragees
Number of subjects: 10
Study 31940011 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Focused Therapy (FFT) - 12 sessions in 4 months of psychoeducation, communication training, and problem-solving skills training
Number of subjects: 127
Study 31940011 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Care - 6 sessions in 4 months of family and individual psychoeducation
Number of subjects: 127
Study 30261917 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (specific dosage not mentioned) administered over 6 weeks
Number of subjects: 60
Study 30261917 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (most promising dose from stage 1)
Number of subjects: 60
Study 30261917 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measures including facial expression recognition, cerebrospinal fluid (CSF) oxytocin levels, and behavioural ratings of videotaped interactions.
Number of subjects: 60
Study 26797192 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level light therapy using the Color DNA-WSF device
Number of subjects: 88
Study 26797192 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with a dummy device
Number of subjects: 88
Study 26405895 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid flower pollination algorithm with randomized location modification
Number of subjects: 0
Study 26405895 — intervention group
Group type: COMPARATOR
Intervention: State-of-the-art evolutionary algorithms (control group)
Number of subjects: 0
Study 24002591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (3 mg per day oral)
Number of subjects: 18
Study 20233517 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg/day)
Number of subjects: 56
Study 17602039 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.45 mg.kg(‐1) iv (1.5 x ED(95))
Number of subjects: 84
Study 17602039 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg.kg(‐1) iv (2.0 x ED(95))
Number of subjects: 84
Study 17602039 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (Group 1)
Number of subjects: 84
Study 17602039 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (Group 3)
Number of subjects: 84
Study 15449263 — intervention group
Group type: EXPERIMENTAL
Intervention: Levatorplasty
Number of subjects: 59
Study 15449263 — intervention group
Group type: COMPARATOR
Intervention: Anal plug electrostimulation of the pelvic floor
Number of subjects: 59
Study 11207463 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ambulation (group A) after total regression of spinal block
Number of subjects: 107
Study 11207463 — intervention group
Group type: COMPARATOR
Intervention: Late mobilisation (group B) bedridden for more than 12 h
Number of subjects: 107
Study 9554360 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral needle ablation of the prostate
Number of subjects: 121
Study 9554360 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate
Number of subjects: 121
Study 8059672 — intervention group
Group type: COMPARATOR
Intervention: 0.05 mmol/kg gadoteridol
Number of subjects: 23
Study 8059672 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mmol/kg gadoteridol
Number of subjects: 23
Study 8059672 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mmol/kg gadoteridol
Number of subjects: 23
Study 8059672 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mmol/kg gadoteridol
Number of subjects: 23
Study 3057923 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (discontinued)
Number of subjects: 21
Study 3057923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30810846 — intervention group
Group type: EXPERIMENTAL
Intervention: S-R-S-R strategy (studying and then retrieving a text two times)
Number of subjects: 0
Study 30810846 — intervention group
Group type: EXPERIMENTAL
Intervention: S-S/J-S-S/J strategy (studying a text four times while completing multiple JOL during the second and fourth repetitions)
Number of subjects: 0
Study 30810846 — intervention group
Group type: COMPARATOR
Intervention: S-S-S-S strategy (studying a text four times)
Number of subjects: 0
Study 30571495 — intervention group
Group type: COMPARATOR
Intervention: Regularly performing no or low-intensity exercise compared with more physical activity
Number of subjects: 1424
Study 30571495 — intervention group
Group type: EXPERIMENTAL
Intervention: Every SD increase in systolic blood pressure
Number of subjects: 1424
Study 30571495 — intervention group
Group type: EXPERIMENTAL
Intervention: History of smoking
Number of subjects: 1424
Study 30571495 — intervention group
Group type: COMPARATOR
Intervention: 5-year follow-up of PVC frequency
Number of subjects: 1424
Study 30571495 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased diastolic blood pressure
Number of subjects: 1424
Study 27265451 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-CRM197 vaccine
Number of subjects: 0
Study 27265451 — intervention group
Group type: COMPARATOR
Intervention: PRP-T vaccine
Number of subjects: 0
Study 27265451 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-CRM197 vaccine with DTaP
Number of subjects: 0
Study 27265451 — intervention group
Group type: COMPARATOR
Intervention: PRP-T vaccine with DTaP
Number of subjects: 0
Study 24302608 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestilan
Number of subjects: 0
Study 24302608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 0
Study 24302608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22800378 — intervention group
Group type: EXPERIMENTAL
Intervention: Department of Geriatrics (DG) treatment pathway including comprehensive geriatric assessment, pain relief, hydration, oxygenation, nutrition, elimination, prevention and management of delirium, assessment of falls and osteoporosis, early mobilization, and individualized rehabilitation plans.
Number of subjects: 0
Study 22800378 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment in the Department of Orthopaedic Surgery (DOS).
Number of subjects: 0
Study 19841897 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vasopressin (0.01-0.03 U/min)
Number of subjects: 778
Study 19841897 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine infusion (5-15 microg/min)
Number of subjects: 778
Study 17478939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg intravenously twice daily
Number of subjects: 30
Study 17478939 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ranitidine)
Number of subjects: 30
Study 17478939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine treatment group
Number of subjects: 30
Study 16983112 — intervention group
Group type: EXPERIMENTAL
Intervention: Exatecan plus gemcitabine (exatecan 2.0 mg/m2 and gemcitabine 1,000 mg/m2 on days 1 and 8, every 3 weeks)
Number of subjects: 349
Study 16983112 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (1,000 mg/m2 up to 7 weeks in the first cycle, then once a week for the first 3 weeks of a 4‐week cycle)
Number of subjects: 349
Study 16983112 — intervention group
Group type: EXPERIMENTAL
Intervention: Exatecan plus gemcitabine
Number of subjects: 349
Study 16983112 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 349
Study 12586182 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 51
Study 12586182 — intervention group
Group type: COMPARATOR
Intervention: Carteolol 2% twice daily and Pilocarpine 2% twice daily
Number of subjects: 51
Study 12586182 — intervention group
Group type: COMPARATOR
Intervention: Carteolol plus Pilocarpine
Number of subjects: 51
Study 10545432 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation
Number of subjects: 79
Study 10545432 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, verapamil, and procainamide
Number of subjects: 79
Study 10545432 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 79
Study 8568135 — intervention group
Group type: EXPERIMENTAL
Intervention: Local nasal immunotherapy with allergen in powder form
Number of subjects: 32
Study 8568135 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 32
Study 1992259 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:100,000 epinephrine
Number of subjects: 92
Study 1992259 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 92
Study 6889140 — intervention group
Group type: EXPERIMENTAL
Intervention: Elixophyllin 400 mg capsule
Number of subjects: 18
Study 6889140 — intervention group
Group type: COMPARATOR
Intervention: Elixophyllin 373 mg elixir
Number of subjects: 18
Study 6889140 — intervention group
Group type: EXPERIMENTAL
Intervention: Theolair 375 mg tablet
Number of subjects: 18
Study 30971235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC) added to high-dose corticosteroids
Number of subjects: 0
Study 30971235 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to high-dose corticosteroids
Number of subjects: 0
Study 26160253 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive early feeding guidelines (enteral and parenteral nutrition)
Number of subjects: 0
Study 26160253 — intervention group
Group type: COMPARATOR
Intervention: Late-onset sepsis
Number of subjects: 0
Study 26160253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient intakes in week 1
Number of subjects: 0
Study 26130358 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty (the Exeter Trauma Stem)
Number of subjects: 56
Study 26130358 — intervention group
Group type: COMPARATOR
Intervention: Internal fixation using the Targon Femoral Plate
Number of subjects: 56
Study 26130358 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 24103901 — intervention group
Group type: EXPERIMENTAL
Intervention: PHEN 7.5 mg/TPM ER 46 mg (7.5/46)
Number of subjects: 475
Study 24103901 — intervention group
Group type: EXPERIMENTAL
Intervention: PHEN 15 mg/TPM ER 92 mg (15/92)
Number of subjects: 475
Study 24103901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study 22936157 — intervention group
Group type: EXPERIMENTAL
Intervention: 1KTWT (1-km treadmill walking test)
Number of subjects: 178
Study 18773214 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 microg)
Number of subjects: 76
Study 18773214 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg)
Number of subjects: 76
Study 18773214 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 76
Study 18773214 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study 17579200 — intervention group
Group type: EXPERIMENTAL
Intervention: VA2914 (5 mg/d)
Number of subjects: 46
Study 17579200 — intervention group
Group type: EXPERIMENTAL
Intervention: VA2914 (10 mg/d)
Number of subjects: 46
Study 17579200 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 46
Study 15222526 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinospora crispa (1 gram thrice daily for 6 months)
Number of subjects: 40
Study 15222526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12667338 — intervention group
Group type: EXPERIMENTAL
Intervention: S + R (surgery plus radiotherapy)
Number of subjects: 495
Study 12667338 — intervention group
Group type: COMPARATOR
Intervention: S (surgery alone)
Number of subjects: 495
Study 10575335 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% halothane
Number of subjects: 27
Study 10575335 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% isoflurane
Number of subjects: 27
Study 10575335 — intervention group
Group type: COMPARATOR
Intervention: Intravenous anesthesia without volatile anesthetics
Number of subjects: 27
Study 7568654 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy (8 sessions)
Number of subjects: 70
Study 7568654 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy plus consultation
Number of subjects: 70
Study 2291838 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1.0 g/day
Number of subjects: 24
Study 2291838 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 2.0 g/day
Number of subjects: 24
Study 2291838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6796885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocodeine
Number of subjects: 12
Study 6796885 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 12
Study 6796885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocodeine plus Oxygen
Number of subjects: 12
Study 6796885 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 12
Study 6796885 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 12
Study 6796885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31919919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg every 2 weeks)
Number of subjects: 149
Study 31919919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 30608515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer screening
Number of subjects: 0
Study 30608515 — intervention group
Group type: COMPARATOR
Intervention: Cohort studies
Number of subjects: 0
Study 27930939 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Parent-delivered Cognitive Behaviour Therapy (GPD-CBT) for 2.6 hours
Number of subjects: 125
Study 27930939 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Parent-delivered Cognitive Behaviour Therapy (GPD-CBT) for 5.3 hours
Number of subjects: 125
Study 27930939 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Parent-delivered Cognitive Behaviour Therapy (GPD-CBT)
Number of subjects: 125
Study 25414250 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-family intervention (n=48)
Number of subjects: 97
Study 25414250 — intervention group
Group type: COMPARATOR
Intervention: Single-family intervention (n=49)
Number of subjects: 97
Study 25414250 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups pooled
Number of subjects: 97
Study 23964994 — intervention group
Group type: EXPERIMENTAL
Intervention: benfotiamine 900 mg/day for 6 weeks
Number of subjects: 22
Study 23964994 — intervention group
Group type: COMPARATOR
Intervention: placebo for 6 weeks
Number of subjects: 22
Study 21971774 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational brochure
Number of subjects: 175
Study 21971774 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 175
Study 21971774 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 175
Study 18310262 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori test and treat (H pylori 13C urea breath test plus one week of eradication treatment if positive)
Number of subjects: 699
Study 18310262 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI) alone
Number of subjects: 699
Study 16990573 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers died at <65 years
Number of subjects: 1117
Study 16990573 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers alive at 65 years but died by 80 years
Number of subjects: 1117
Study 16990573 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers alive at 80 years
Number of subjects: 1117
Study 16990573 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean common carotid arteries intima-media thickness in subjects with premature paternal death
Number of subjects: 1117
Study 16990573 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean PWV in the 3 groups of paternal longevity
Number of subjects: 1117
Study 14566995 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate breakfast
Number of subjects: 24
Study 14566995 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat and protein breakfast
Number of subjects: 24
Study 14566995 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical breakfast
Number of subjects: 24
Study 14566995 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 24